AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27788679 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation program using augmented reality
Number of subjects: 70
Study 27788679 — intervention group
Group type: COMPARATOR
Intervention: Standard treadmill training
Number of subjects: 70
Study 24084003 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic interval training (AIT)
Number of subjects: 32
Study 24084003 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic training (CoAT)
Number of subjects: 32
Study 23248829 — intervention group
Group type: COMPARATOR
Intervention: 3-in-1 block
Number of subjects: 60
Study 23248829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 60
Study 20462090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsler grid testing interpreted by a rheumatologist
Number of subjects: 140
Study 20462090 — intervention group
Group type: COMPARATOR
Intervention: Humphrey 10‐2 fields testing interpreted by an ophthalmologist
Number of subjects: 140
Study 19075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of cereal allergens
Number of subjects: 0
Study 19075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of cereal allergens
Number of subjects: 0
Study 19075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific response to CM3 in celiac disease
Number of subjects: 0
Study 15901232 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Peer Treatment (RPT)
Number of subjects: 82
Study 15901232 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 82
Study 12918893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of docetaxel (Taxotere) and capecitabine (Xeloda)
Number of subjects: 0
Study 12918893 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 0
Study 10536358 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analysis of HER-2/neu gene amplification
Number of subjects: 61
Study 10536358 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated fluorescence ratio (IFR)
Number of subjects: 61
Study 10536358 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage positive nuclear area (PPN)
Number of subjects: 61
Study 10536358 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitation of amplification fluorescence signal using image analysis
Number of subjects: 61
Study 8732122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release tablets of Tripterygium wilfordii (TW‐SR), 2 tablets, twice a day for 4 weeks
Number of subjects: 226
Study 8732122 — intervention group
Group type: COMPARATOR
Intervention: Tablets of Tripterygium wilfordii (TW), 2 tablets, 3 times per day for 4 weeks
Number of subjects: 226
Study 1831755 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Number of subjects: 32
Study 1831755 — intervention group
Group type: COMPARATOR
Intervention: 3.6 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Number of subjects: 32
Study 1831755 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (both dosages)
Number of subjects: 32
Study 6415735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride 5 micrograms/kg
Number of subjects: 11
Study 6415735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30311987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oncolytic treatment
Number of subjects: 272
Study 30311987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake and time-varying CES-D20
Number of subjects: 272
Study 30517572 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation containing chamomile microparticles coated with chitosan
Number of subjects: 35
Study 30517572 — intervention group
Group type: COMPARATOR
Intervention: Base formulation
Number of subjects: 35
Study 30517572 — intervention group
Group type: COMPARATOR
Intervention: Formulation with microparticles
Number of subjects: 35
Study 26403703 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breast milk supplementation with 2g of a multinutrient supplement (Pré-Nan(®), Nestlé) added to expressed breast milk twice a day until a corrected age of 4-6 months.
Number of subjects: 53
Study 26403703 — intervention group
Group type: COMPARATOR
Intervention: Control group exclusively breastfed without supplementation.
Number of subjects: 53
Study 24231400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment-BIG (BIG; 16 hours over 4 weeks)
Number of subjects: 60
Study 24231400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (WALK; 16 hours over 8 weeks)
Number of subjects: 60
Study 24231400 — intervention group
Group type: COMPARATOR
Intervention: Nonsupervised domestic exercise (HOME; 1 hour instruction)
Number of subjects: 60
Study 24231400 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BIG and WALK groups
Number of subjects: 60
Study 23206968 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning group with free access to a Web site on musculoskeletal palpation and ultrasound assessment
Number of subjects: 44
Study 23206968 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to documents and books on the topic
Number of subjects: 44
Study 20953746 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hyaluronic acid and hypertonic saline
Number of subjects: 20
Study 20953746 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline alone
Number of subjects: 20
Study 17333159 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg orally twice daily for 3 days
Number of subjects: 10
Study 17333159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16279906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (7 mg iron/kg body weight, followed by five 200 mg infusions over 5 weeks)
Number of subjects: 46
Study 16279906 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulfate (100-200 mg per day for 6 weeks)
Number of subjects: 46
Study 11296939 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE strategy
Number of subjects: 11
Study 11296939 — intervention group
Group type: COMPARATOR
Intervention: SPEAK
Number of subjects: 11
Study 11296939 — intervention group
Group type: COMPARATOR
Intervention: CIS
Number of subjects: 11
Study 11296939 — intervention group
Group type: EXPERIMENTAL
Intervention: All three strategies
Number of subjects: 11
Study 9834991 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest irradiation combined with chemotherapy
Number of subjects: 15
Study 9834991 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 15
Study 7984118 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Number of subjects: 41
Study 2605388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 55
Study 2605388 — intervention group
Group type: COMPARATOR
Intervention: Self-management training
Number of subjects: 55
Study 4776883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2,000 international units daily for three months)
Number of subjects: 226
Study 4776883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 4776883 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 226
Study 4776883 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant treatment
Number of subjects: 226
Study 31741641 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depression using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 339
Study 31741641 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 339
Study 31741641 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 339
Study 28293624 — intervention group
Group type: EXPERIMENTAL
Intervention: High Blood Pressure Group (HBPG)
Number of subjects: 571
Study 28293624 — intervention group
Group type: COMPARATOR
Intervention: Normal Blood Pressure Group (NBPG)
Number of subjects: 571
Study 26206641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic silver-containing dressing (ISD)
Number of subjects: 147
Study 26206641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment application (MOA)
Number of subjects: 147
Study 26206641 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (standard dressing)
Number of subjects: 147
Study 23328389 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil diolamine (oral sustained release tablets), chronic dosing (twice-daily)
Number of subjects: 74
Study 20977377 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic near-infrared light treatment (12 sessions of 30 minutes each over 4 weeks)
Number of subjects: 34
Study 20977377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study 20977377 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic near-infrared light treatment
Number of subjects: 34
Study 19063651 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perception of organizational commitment to employee health
Number of subjects: 899
Study 19063651 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceptions of coworker healthy eating behaviors
Number of subjects: 899
Study 19063651 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceptions of coworker physical activity behaviors
Number of subjects: 899
Study 17947731 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1565
Study 15480319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with omega-3 fatty acids
Number of subjects: 526
Study 15480319 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite allergen avoidance
Number of subjects: 526
Study 15480319 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonatopic children)
Number of subjects: 526
Study 11202867 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtura II (group C)
Number of subjects: 40
Study 11202867 — intervention group
Group type: COMPARATOR
Intervention: Lateral compaction (group A)
Number of subjects: 40
Study 11202867 — intervention group
Group type: COMPARATOR
Intervention: Hybrid technique (group B)
Number of subjects: 40
Study 11202867 — intervention group
Group type: COMPARATOR
Intervention: Thermafil (group D)
Number of subjects: 40
Study 9371358 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.375 g piperacillin-tazobactam every 6 hours
Number of subjects: 12
Study 9371358 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g piperacillin-tazobactam every 8 hours
Number of subjects: 12
Study 9371358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 12
Study 1438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Early advice group
Number of subjects: 0
Study 1438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Late advice group
Number of subjects: 0
Study 1438110 — intervention group
Group type: COMPARATOR
Intervention: Control group (families with no cardiovascular disease)
Number of subjects: 0
Study 3914805 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII (Continuous Subcutaneous Insulin Infusion)
Number of subjects: 45
Study 3914805 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily mixed rapid and long acting insulin
Number of subjects: 45
Study 3914805 — intervention group
Group type: COMPARATOR
Intervention: Multiple s.c. injections via butterfly 5-6x daily
Number of subjects: 45
Study 30920278 — intervention group
Group type: COMPARATOR
Intervention: Targeted identity-safety interventions (combined social-belonging, values-affirmation, and growth-mindset interventions)
Number of subjects: 806
Study 30920278 — intervention group
Group type: COMPARATOR
Intervention: Growth-mindset only treatment
Number of subjects: 806
Study 30920278 — intervention group
Group type: COMPARATOR
Intervention: Social-belonging intervention alone
Number of subjects: 806
Study 30920278 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal analyses of interventions
Number of subjects: 806
Study 29589098 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 153
Study 29589098 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 153
Study 27881103 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclegis® (doxylamine succinate and pyridoxine hydrochloride)
Number of subjects: 256
Study 27881103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 24506079 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and DCS
Number of subjects: 57
Study 24506079 — intervention group
Group type: COMPARATOR
Intervention: CBT and placebo
Number of subjects: 57
Study 23235413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation (TS) along with standard treatment (antiaggregant vascular drugs and hypocaloric diet)
Number of subjects: 85
Study 23235413 — intervention group
Group type: COMPARATOR
Intervention: Placebo TS procedures with turned-off electrodes (Control group)
Number of subjects: 85
Study 19598217 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular resonance tonsillectomy (MRT)
Number of subjects: 157
Study 19598217 — intervention group
Group type: COMPARATOR
Intervention: Coblation tonsillectomy (CAT)
Number of subjects: 157
Study 17599445 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 2202
Study 17599445 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 2202
Study 17599445 — intervention group
Group type: COMPARATOR
Intervention: Noninducible patients
Number of subjects: 2202
Study 17599445 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 2202
Study 17599445 — intervention group
Group type: EXPERIMENTAL
Intervention: Event classification
Number of subjects: 2202
Study 14734454 — intervention group
Group type: EXPERIMENTAL
Intervention: Large multivalent immunogen (LMI) administered without adjuvant, one-half intradermally (i.d.) and the other half subcutaneously (s.c.) at doses of 10-, 30-, or 100-million tumor cell equivalents on weeks 0, 4, and 8.
Number of subjects: 15
Study 14625516 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplement 0.5 g/kg body mass/day
Number of subjects: 12
Study 14625516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 12
Study 14625516 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation discontinued after 4 weeks
Number of subjects: 12
Study 10668490 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3 gm daily; 1200 mg elemental calcium)
Number of subjects: 930
Study 10668490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 8542115 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 26
Study 8542115 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study 1712206 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (LD)
Number of subjects: 14
Study 1712206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6224507 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical handicap
Number of subjects: 0
Study 6224507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental handicap
Number of subjects: 0
Study 6224507 — intervention group
Group type: COMPARATOR
Intervention: Sex of the respondent
Number of subjects: 0
Study 6224507 — intervention group
Group type: COMPARATOR
Intervention: Contact with disabled people
Number of subjects: 0
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Risordan (20 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Corditrine
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release Trinitrin (2.5 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release Trinitrin (5 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenitral (7.5 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Langoran (40 mg)
Number of subjects: 50
Study 2871818 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinitrin skin patch (10 mg)
Number of subjects: 50
Study 29294649 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in sensitive research about abuse and intimate partner violence
Number of subjects: 3264
Study 29294649 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims of abuse
Number of subjects: 3264
Study 29294649 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrators of abuse
Number of subjects: 3264
Study 29451926 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 20
Study 29451926 — intervention group
Group type: COMPARATOR
Intervention: Coronally Advanced Flap plus Subepithelial Connective Tissue Graft (CAF + CTG)
Number of subjects: 20
Study 26719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab for patients with BRVO
Number of subjects: 492
Study 26719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab for themselves
Number of subjects: 492
Study 26719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab for patients with CRVO
Number of subjects: 492
Study 26719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal preference among biologics for themselves (aflibercept 30.6%, bevacizumab 36.5%, ranibizumab 32.9%)
Number of subjects: 492
Study 25700557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-implementation group
Number of subjects: 1136
Study 25700557 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher Implementation and Student Reception
Number of subjects: 1136
Study 25700557 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher implementation components
Number of subjects: 1136
Study 23819827 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral contract intervention for 1 year
Number of subjects: 150
Study 23819827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behavioral contract)
Number of subjects: 150
Study 20537314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) training with abdominal muscle training
Number of subjects: 57
Study 20537314 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle (PFM) training without abdominal muscle training
Number of subjects: 57
Study 18789958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin plus leuprolide acetate (LA) at 1mg/day (Group 2)
Number of subjects: 14
Study 18789958 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophins only (Group 1)
Number of subjects: 14
Study 16885120 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol HCl (75 microg)
Number of subjects: 24
Study 16885120 — intervention group
Group type: COMPARATOR
Intervention: Procaterol HCl pellets capsule
Number of subjects: 24
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (A)
Number of subjects: 0
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin Z250 (B)
Number of subjects: 0
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP (C)
Number of subjects: 0
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP (F)
Number of subjects: 0
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC/Z250 (D)
Number of subjects: 0
Study 14535057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP/composite resin Z250 (E)
Number of subjects: 0
Study 14535057 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10950051 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisone
Number of subjects: 18
Study 10950051 — intervention group
Group type: COMPARATOR
Intervention: 3 mg budesonide
Number of subjects: 18
Study 10950051 — intervention group
Group type: COMPARATOR
Intervention: 9 mg budesonide
Number of subjects: 18
Study 8636290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (water only) for 5 days
Number of subjects: 8
Study 1362137 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (75 to 150 mg daily, 25-50 mg t.i.d. for 3 weeks)
Number of subjects: 40
Study 1362137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Container 1 (outstanding on almost every attribute)
Number of subjects: 99
Study 6421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Container 2 (preferred over others on most attributes)
Number of subjects: 99
Study 6421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Container 3 (preferred over others on most attributes)
Number of subjects: 99
Study 6421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Container 4 (preferred over others on most attributes)
Number of subjects: 99
Study 6421438 — intervention group
Group type: EXPERIMENTAL
Intervention: Containers with flip off tops, long threads, very small size, and glass
Number of subjects: 99
Study 31390090 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent programme combining knee OA-specific therapeutic exercise with self-management support
Number of subjects: 56
Study 31390090 — intervention group
Group type: COMPARATOR
Intervention: Routine group exercise programme
Number of subjects: 56
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antenatal care (ANC) utilization
Number of subjects: 922
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and living in a wealthy household
Number of subjects: 922
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohabitating and single/unmarried status
Number of subjects: 922
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in urban areas
Number of subjects: 922
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 922
Study 29703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of women and age of last child
Number of subjects: 922